McKesson Corporation 10-Qquarter ended 2026-09-30

Executive Summary

McKesson earns money distributing medicines and medical supplies to pharmacies and healthcare providers, supporting specialty practices, and providing prescription-access services. It is expanding oncology and multispecialty services while preparing Medical-Surgical Solutions for separation. Q2 FY2027 revenue rose 7.6%, with pharmaceutical volumes supporting faster operating-profit growth, although settlements and prior-year charges complicate the earnings comparison. Recent acquisitions deepen its specialty-care opportunity, but higher debt, minority-owner claims and substantial shareholder payouts make the cash available to McKesson shareholders increasingly important.

What's Happening in the Business

Pharmaceutical distribution remains the engine. Institutional customers and national retail accounts bought more medicines, including GLP-1 treatments and new launches; branded-drug price declines and conversions to generics partly offset that demand. Specialty pharmaceutical sales and provider services also expanded, although Oncology & Multispecialty’s quarterly growth slowed relative to H1.

McKesson is extending that specialty-care platform. After quarter-end, it completed acquisitions of Precision Medicine Group for ≈$2.25B and a controlling interest in Spectrum Vision Partners for ≈$525M. Both enter Oncology & Multispecialty beginning in Q3. It also agreed to acquire 49% of Option Care Health for ≈$1.4B, with closing expected in H1 calendar 2027, subject to approvals.

Medical-Surgical Solutions is moving toward independence. Apollo-managed funds invested ≈$1.25B for an ≈13% minority interest, while subsidiaries raised secured term loans to repay an intercompany loan. McKesson retains control and consolidates the business, but separation expenses and weaker ambulatory-care contributions are depressing its profit.

Restructuring spans the remaining company: a new corporate operating-model initiative carries expected charges of $230M–$310M through substantial completion in FY2028, alongside prescription-technology and enterprise-modernization programs.

Key Financial Highlights

Q2 and H1 FY2027 ended 9/30/2026; changes are Y/Y unless stated.

• Pharmaceutical earnings quality: Q2 antitrust settlements reduced cost of sales by $50.0M. H1 also benefited from comparison with a $189M prior-year Rite Aid bankruptcy provision; these are not repeatable volume gains.
• Oncology comparison: Q2 revenue growth slowed from H1’s 29%, while profit growth lagged H1’s 24%. Higher costs and the absence of a prior-year $51.0M investment-sale/market-decision gain explain part of that gap.
• Prescription and medical-surgical costs: Higher third-party logistics volumes and prescription-access demand supported technology profits, but H1 restructuring charges of $79.0M left H1 profit nearly flat. Medical-Surgical separation charges were $42.0M in Q2 and $87.0M in H1. Outside the segments, Q2 corporate expenses were $211M, including $52.0M of restructuring charges; segment profits also include other income excluded from consolidated operating income.
• Minority interests: H1 net income total (incl. noncontrolling interests) was $2.33B, +17%. A $391M redemption-value adjustment increased the amount assigned to redeemable minority owners, reducing income attributable to McKesson without reducing operating income.
• Cash and capital returns: Supplier-payment timing contributed a $2.6B improvement to OCF, partly offset by inventory, receivables and taxes. H1 FCF was $2.58B, against cash repurchases of $3.42B vs $1.40B and dividends of $198M vs $179M. Shares outstanding fell ≈4.2% since fiscal year-end to ≈115M.

Risk Assessment

• Financing and capital allocation: Higher borrowing, shareholder payouts exceeding FCF, and acquisition spending reduce flexibility; H1 interest expense rose 48% to $182M, although the new $5.0B revolving facility was undrawn.
• Opioid litigation: Recorded liabilities of $5.16B require continuing settlement payments, while unresolved claims could produce additional losses that cannot yet be reasonably estimated.
• Separation and minority ownership: Medical-Surgical’s weaker profitability and new financing complicate separation, while redemption rights can reduce earnings available to McKesson shareholders.
• Healthcare policy: Changes to drug pricing, the federal 340B program and government healthcare funding could alter pharmaceutical economics and reduce acquired-business valuations.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: the company's 10-Ks on SEC.

What to Watch

• Specialty expansion: The completed acquisitions and pending Option Care investment should broaden services beyond drug distribution; later filings will show whether acquired operations sustain growth or bring integration costs and write-downs.
• Medical-Surgical separation: Revenue is growing but profit is falling; improving ambulatory-care contribution and declining separation charges would support readiness for independence, while persistent weakness would undermine it.
• Cash allocation: Buybacks exceeded H1 FCF before the latest acquisitions; future filings will show whether recurring cash generation supports these commitments or borrowing continues to rise.